Literature DB >> 10776829

Kinase inhibitors in cancer therapy: a look ahead.

H H Sedlacek1.   

Abstract

The most essential kinases involved in cell membrane receptor activation, signal transduction and cell cycle control or programmed cell death and their interconnections are reviewed. In tumours, the genes of many of those kinases are mutated or amplified or the proteins are overexpressed. The use of key kinases offers the possibility to screen in vitro for synthetic small molecule kinase inhibitors. In view of the many interconnections of cellular kinases, their role in preventing or inducing programmed cell death and the possibility that a considerable number of signal transducing proteins are still unknown, cellular test systems are recommended in which the respective key kinase or one of its main partner molecules are overexpressed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10776829     DOI: 10.2165/00003495-200059030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  436 in total

1.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.

Authors:  F Mercurio; H Zhu; B W Murray; A Shevchenko; B L Bennett; J Li; D B Young; M Barbosa; M Mann; A Manning; A Rao
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

2.  Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas.

Authors:  S Eggstein; G Manthey; T Hirsch; F Baas; B U Specht; E H Farthmann
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease.

Authors:  M J Pollman; J L Hall; M J Mann; L Zhang; G H Gibbons
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

4.  Insulin-like growth factor I receptors on mouse neuroblastoma cells. Two beta subunits are derived from differences in glycosylation.

Authors:  A Ota; G L Wilson; D Leroith
Journal:  Eur J Biochem       Date:  1988-06-15

5.  Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph.

Authors:  Y Maru; H Hirai; M C Yoshida; F Takaku
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

6.  Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro.

Authors:  D T Zava; G Duwe
Journal:  Nutr Cancer       Date:  1997       Impact factor: 2.900

7.  Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C.

Authors:  R Marais; Y Light; C Mason; H Paterson; M F Olson; C J Marshall
Journal:  Science       Date:  1998-04-03       Impact factor: 47.728

8.  Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients.

Authors:  R Lidereau; D Mathieu-Mahul; C Theillet; M Renaud; M Mauchauffé; J Gest; C J Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2.

Authors:  D Desai; H C Wessling; R P Fisher; D O Morgan
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

10.  Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma.

Authors:  S Ikeda; H Sumii; K Akiyama; S Watanabe; S Ito; H Inoue; H Takechi; G Tanabe; T Oda
Journal:  Jpn J Cancer Res       Date:  1989-01
View more
  10 in total

1.  Transmembrane helix predictions revisited.

Authors:  Chien Peter Chen; Andrew Kernytsky; Burkhard Rost
Journal:  Protein Sci       Date:  2002-12       Impact factor: 6.725

Review 2.  ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.

Authors:  Jiexin Deng; Jie Shao; John S Markowitz; Guohua An
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

3.  Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Authors:  Fleur Broekman; Elisa Giovannetti; Godefridus J Peters
Journal:  World J Clin Oncol       Date:  2011-02-10

4.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

5.  Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights.

Authors:  Wagdy M Eldehna; Raed M Maklad; Hadia Almahli; Tarfah Al-Warhi; Eslam B Elkaeed; Mohammed A S Abourehab; Hatem A Abdel-Aziz; Ahmed M El Kerdawy
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 6.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

7.  Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate.

Authors:  Joan Manel Gasent Blesa; Enrique Grande Pulido; Juan Laforga Canales; Vicente Alberola Candel
Journal:  Case Rep Oncol       Date:  2009-12-11

8.  Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.

Authors:  Stephanie E Combs; Steffen Heeger; Renate Haselmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2006-05-18       Impact factor: 4.430

9.  Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies.

Authors:  Wagdy M Eldehna; Sara T Al-Rashood; Tarfah Al-Warhi; Razan O Eskandrani; Amal Alharbi; Ahmed M El Kerdawy
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

10.  Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.

Authors:  Mai Maher; Asmaa E Kassab; Ashraf F Zaher; Zeinab Mahmoud
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.